Key facts
- This page summarizes Nadia Waheed's Form 4 filing for OCULAR THERAPEUTIX, INC (OCUL).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 04 Jun 2024, 17:28.
Nadia Waheed - 01 Jun 2024 Form 4 Insider Report for OCULAR THERAPEUTIX, INC (OCUL)
- Reporting relationship
- Chief Medical Officer
- Issuer ticker
- OCUL
- Reported as of
- 01 Jun 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 04 Jun 2024, 17:28:11 UTC
- Next SEC filing
- 13 Feb 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/ Donald Notman, Attorney-in-Fact for Nadia Waheed
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Filing notes and source
Key filing fact
Nadia Waheed filed Form 4 for OCULAR THERAPEUTIX, INC (OCUL) on 04 Jun 2024.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
OCUL
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +141,666
- Change %
- Price
- $0.000000
- Shares after
- 141,666
- Date
- 01 Jun 2024
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
OCUL
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +425,000
- Change %
- Price
- $0.000000
- Shares after
- 425,000
- Date
- 01 Jun 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 425,000
- Exercise price
- $5.70
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
On June 1, 2024, the reporting person was granted restricted stock units ("RSUs") under the 2019 Inducement Stock Incentive Plan, as amended, of Ocular Therapeutix, Inc. (the "Corporation"). Each RSU represents a right to receive one share of the Corporation's common stock. Subject to the reporting person's continued service to the Corporation, the RSUs will vest over three years, in equal annual installments, beginning on the date of grant.
Footnote F2
Vests over four years, with 25% of the shares underlying the option vesting on the one-year anniversary of the reporting person's first date of employment and 2.0833% of the shares vesting monthly thereafter.